Stephen Fadem, MD
Nephrology · Houston, TXNPI 1144224163
Payments from drug & device makers
Across 397 payments — averaging $6165.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2.3M
- Akebia Therapeutics Inc$83K
- AstraZeneca$38K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$28K
- Biogen$28K
- Ardelyx, Inc.$4K
- plus $3K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 84 | $2,264,884 |
| Akebia Therapeutics Inc | 197 | $83,281 |
| AstraZeneca | 21 | $37,534 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $27,897 |
| Biogen | 2 | $27,892 |
| Ardelyx, Inc. | 7 | $3,633 |
| Amgen(2 entities) | 36 | $1,182 |
| Otsuka America Pharmaceutical, Inc. | 8 | $234 |
| GSK | 5 | $209 |
| Aurinia Pharma U.S., Inc. | 2 | $153 |
| Fresenius USA Marketing, Inc. | 3 | $140 |
| OPKO Pharmaceuticals, LLC | 4 | $98 |
| Renalytix AI, Inc. | 1 | $94 |
| Vifor Pharma, Inc. | 3 | $89 |
| Boehringer Ingelheim | 1 | $86 |
| Abbott | 1 | $83 |
| Mallinckrodt Enterprises LLC | 5 | $80 |
| Novartis | 3 | $64 |
| Angiodynamics, Inc. | 1 | $32 |
| Pfizer | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Amicus Therapeutics, Inc. | 1 | $19 |
| Travere Therapeutics, Inc. | 2 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Bayer | 1 | $14 |
How this compares
$2,447,793 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Houston
- Sreedhar MandayamHouston$7M
- Marializa BernardoHouston$4.2M
- Biruh WorkenehHouston$1.8M
- Rahul PandeyHouston$1.6M
- Christopher KwohHouston$928K
- George NassarHouston$772K
- June YaoHouston$651K
- Maher BisharaHouston$489K
- Wolfgang WinkelmayerHouston$462K
- Dana MitchellHouston$460K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.